Piper Sandler thinks Myriad Genetics (MYGN), which has seen its shares fall nearly 22% on Friday morning, is trading down on a coverage decision on GeneSight by UnitedHealth (UNH), which will take ...
BRANDON, FL, UNITED STATES, November 3, 2024 /EINPresswire / -- Learning to Achieve Wellness has carved out a unique space in the world of mental < ...
UnitedHealth (UNH) on Friday disclosed that it would stop covering multi-panel pharmacogenetic tests, including Myriad’s (MYGN) GeneSight, effective January 1, 2025, in a number of plans ...
With a simple cheek swab, the GeneSight test generates a report that gives healthcare providers insight into how a patient may metabolize or respond to certain psychiatric medications.